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Melanoma predisposition—A limited role for germline BRCA1 
and BRCA2 variants
David J. Adams  |   David Timothy Bishop |   Carla Daniela Robles‐Espinoza
For several decades, the role of germline BRCA1/BRCA2 variants in 
predisposition to melanoma has been controversial. Several groups 
have reported a positive association between BRCA variant status 
and melanoma formation, while other studies have failed to find an 
association (Gumaste et al., 2015). In the same way, analyses of fa‐
milial melanoma cohorts have reported germline pathogenic alleles 
of BRCA2 (Gumaste et al., 2015; Tuominen et al., 2016) providing 
some evidence that germline variants in these genes might contrib‐
ute to disease pathogenesis—but do they?
The potential involvement of germline BRCA variants in melanoma 
susceptibility has profound implications for patient management and 
screening, since there are now agents such as poly‐(ADP‐ribose)‐
polymerase (PARP) inhibitors (Farmer et al., 2005) that could be used 
to treat tumours from carrier patients, or even potentially prophy‐
lactically to prevent tumour formation. Further, several commercial 
vendors promote BRCA1/2 testing in patients with a history of mel‐
anoma, so it is important for patients and the healthcare system to 
establish whether such testing is warranted, not only because of the 
associated cost but also because genetic testing can be associated 
with significant patient anxiety.
The tumour spectrum associated with germline BRCA variants 
has largely been elucidated by examining the cancer history of carri‐
ers and presumed carriers in families identified because of multiple 
cases of breast or ovarian cancer. Of course, other cancers occur in 
these families both by chance but also potentially because the germ‐
line variant increases cancer risk. Typically, the observed numbers of 
cancers in carriers are compared to the incidence of these cancers in 
the general population, but the power of individual studies is usually 
low because the number of actual carriers is limited. So why might 
the association between BRCA alleles and melanoma be inconsis‐
tent? Firstly, it is possible that BRCA alleles have no effect and that 
chance variation provides a statistical signal suggesting an associa‐
tion between these variants and melanoma. Secondly, that there is 
a modest effect and again chance variation plays a role. Thirdly, that 
any effect is limited to a subset of BRCA variants (e.g., the Ovarian 
Cancer Cluster Region which is associated with a much higher rela‐
tive risk of ovarian cancer than other variants in BRCA1 or BRCA2 
(Rebbeck et al., 2015)) and that the variant profile differs in differ‐
ent cohorts. Finally, melanoma risk is not uniform across populations 
because common melanoma risk factors including pigmentation and 
nevi (which are unrelated to BRCA genotype) are polygenic. These 
variants, such as the R alleles of MC1R, are known to be able to in‐
fluence the risk of melanoma development even in individuals with 
established high‐penetrance melanoma predisposition alleles such 
as pathogenic variants in CDKN2A. Identifying a suitable control 
population of a sufficient size, that is well‐matched to carriers and 
has the same melanoma polygenic risk profile, poses an additional 
problem and can confound the analysis.
In a large‐scale and exhaustive study of cancers by the IMPACT 
team at Memorial Sloan Kettering Cancer Centre by Jonsson and 
collaborators, where cancer patients being treated at the hospi‐
tal were uniformly ascertained and whose tumour and germline 
genomic sequences were systematically analysed by targeted se‐
quencing, the authors were able to show that if germline BRCA1 
or BRCA2 variants do contribute to the population burden of mel‐
anoma predisposition then this contribution is modest. What is 
particularly special about this study is that the scale of the patient 
cohort (17,152 patients, 55 tumour types, 621 melanoma patients) 
meant that statistically robust conclusions could be derived. By 
analysis of these patients, clear and unequivocal associations be‐
tween germline and somatic BRCA1/2 variants and ovarian, pros‐
tate, breast and pancreas cancer (the BRCA‐associated cancer 
types) were observed, as well as a potentially novel association be‐
tween somatic mutations in BRCA2 and uterine sarcomas. Indeed, 
it was only in the BRCA‐associated cancer types that genomic 
analysis was able to find a significant level of somatic loss‐of‐het‐
erozygosity (LOH) consistent with the recessive model of tumour 
suppressor gene function. In comparison, when the same analysis 
was done on non‐BRCA‐associated cancer types (which includes 
melanoma), tumour‐specific loss of the germline pathogenic al‐
lele instead of the wild‐type allele was observed more frequently, 
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further suggesting that loss of BRCA1 or BRCA2 did not contrib‐
ute to these cancers. Moreover, it was only in ovarian, prostate, 
breast and pancreas cancer that the diagnostic single nucleotide 
pattern associated with loss of homologous recombination could 
be observed, with only a modest increase of this signature in non‐
BRCA‐associated cancer types with biallelic BRCA inactivation. 
For the other cancer sites, only between 0.5% and a few per cent 
of cases had a germline BRCA variant (1% for melanoma). These 
figures are broadly in keeping with the make‐up of the popula‐
tion studied of whom more than 18% were of Ashkenazi descent, 
a population known to have a high carrier rate of BRCA variants. 
As for the 621 melanoma patients in the study, there were 258 
females and 363 males, and the mean and median age at first diag‐
nosis were 56.9 and 59 years old, respectively, with age unknown 
for 26 patients.
Another key observation of this study was that while patients 
from BRCA‐associated cancer types that had a germline, poten‐
tially pathogenic BRCA variant derived greater clinical benefit 
from PARP inhibitor treatment than those without these variants, 
this was not true for patients with non‐BRCA‐associated cancers. 
Although their analysis only included one melanoma patient, it 
suggests that germline testing should not be the only criterium by 
which patient treatment is chosen and that other aspects such as 
tumour lineage might play an equal, if not more important, role in 
therapy response.
Are there any limitations of the current study? In the context of 
melanoma, the authors grouped together all melanoma subtypes in‐
cluding cutaneous, uveal, acral and mucosal melanoma. It is known 
that the genomes of these different melanoma subtypes are dis‐
tinctly different, with the genomes of uveal, acral and mucosal mel‐
anoma being characterized by a high level of copy number gains and 
losses, while the genomes of cutaneous melanoma are replete with 
UV‐induced C > T mutations. By “pooling” all subtypes together in 
this way it is possible that any statistical signal that might link BRCA1 
or BRCA2 variants to rarer melanoma subtypes could be diluted. That 
said, on balance, it seems unlikely that germline BRCA1 or BRCA2 
variants profoundly contribute to any melanoma subtype. It should 
be noted that large‐scale studies of this type cannot conclude that 
BRCA1 or BRCA2 variants never contribute to melanoma formation, 
just that at a population level they are not major contributors to the 
burden of disease.
In summary, Jonsson et al. have made a significant contribution 
to the debate on the involvement of BRCA1 and BRCA2 variants to 
melanoma predisposition and provide a reminder that we must con‐
stantly revisit gene‐disease associations so as to better counsel pa‐
tients about their care.
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